மரபியல் குழு News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from மரபியல் குழு. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In மரபியல் குழு Today - Breaking & Trending Today
There are two certainties about the Covid-19 vaccines being mass-distributed around the world. The first is that governments and the vast majority of mainstream media are pushing with as much ferocity as they can muster for these experimental drugs to be injected into as many people as possible. The second is that those who are brave enough to face the scorn that comes with asking serious questions about the vaccines are absolutely necessary components of our ongoing fight to spread the truth. NOQ Report received an advanced copy of the manuscript in preprint below. It has been prepared by nearly five dozen highly respected doctors, scientists, and public policy experts from across the globe to be urgently sent to world leaders as well as all who are associated with the production and distribution of the various Covid-19 vaccines in circulation today. ....
ADVERTISEMENT Winning Arabian racehorses might owe their success, at least in part, to three specific genes. According to a recent study, Arabians with certain genes coding for less muscle fatigue, more time-efficient energy production, and improved muscular contraction have better racing results than those that don’t. By recognizing and selecting for these genes, breeders could fine-tune their production techniques, which could lead to fewer unsuccessful racehorses that often end up removed from the racing industry. “Although slower than environmental interventions (such as changes in management and training), genetic changes are known to accumulate over generations and, thus, genetic research provides an avenue for more permanent change,” said Brandon Velie, BSc, MSc, PhD, of the Equine Genetics and Genomics Group at the University of Sydney. ....
The FDA has approved the PD-L1 IHC 22C3 pharmDx assay, developed by Agilent Technologies Inc, for expanded use in patients with non–small cell lung cancer. ....
Industry News: Agilent PD-L1 IHC 22C3 pharmDx receives expanded FDA approval in non-small cell lung cancer Companion diagnostic can help guide treatment decisions in cases of NSCLC 23 Feb 2021 Agilent Technologies Inc. has announced that the U.S. Food and Drug Administration (FDA) has approved the company’s PD-L1 IHC 22C3 pharmDx assay for expanded use in patients with non-small cell lung cancer (NSCLC). PD-L1 IHC 22C3 pharmDx can now be used as an aid in identifying NSCLC patients with tumor PD-L1 expression of Tumor Proportion Score (TPS) ≥ 50% for treatment with Libtayo ® (cemiplimab-rwlc). This announcement underscores Agilent s continuing commitment to the development of IHC-based diagnostics for cancer therapy. ....